|
Post by ashiwi on Mar 23, 2014 19:28:20 GMT -5
I like your optimism Spiro, Don't forget Spiro and I heard it right from upper management's mouth . They think that the "Cricket" device for acute pain will be bigger than Afrezza. It's currently being tested at Torrey Pines in St Lucie, Fl. The flood gates will be open for Technosphere once Afrezza gets approved. I also believe that Al Mann will ultimately sell the company. He is already working on his Basal Insulin Patch with another privately held company. The CRL 3 years ago has slowed down the basal insulin patch progress, but Al Mann is very excited about it. Either way the next few weeks will be very interesting.
|
|
|
Post by brentie on Mar 23, 2014 21:39:53 GMT -5
I like your optimism Spiro, Don't forget Spiro and I heard it right from upper management's mouth . They think that the "Cricket" device for acute pain will be bigger than Afrezza. It's currently being tested at Torrey Pines in St Lucie, Fl. The flood gates will be open for Technosphere once Afrezza gets approved. I also believe that Al Mann will ultimately sell the company. He is already working on his Basal Insulin Patch with another privately held company. The CRL 3 years ago has slowed down the basal insulin patch progress, but Al Mann is very excited about it. Either way the next few weeks will be very interesting. Which brings up an interesting question. Does anybody know what the FDA will require for each different drug that's loaded onto Technosphere to get to market? Will each individual drug have to go through many years of trials like Afrezza? By the way, the company that ashiwi referred to with the basal patch pump is called PerQFlo. Alfred E. Mann Second Sight Alfred E. Mann has founded and largely funded 17 companies in his career. Two companies became public and ten were acquired at an overall total of almost $8 billion. The companies currently within the family: • MannKind Corporation, which develops novel therapeutics and drug delivery technologies for treatment primarily of diabetes, metabolic disease and cancer; • Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs to address peripheral pain; • Second Sight, which is developing visual prostheses to restore sight to the blind; • IncuMed, which is developing novel percutaneous seals for various applications; • PerQFlo, which is developing drug delivery systems; and• Quallion, which develops, manufactures and markets advanced batteries for medical, aerospace and military applications. Additionally, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. from its founding in 1993 until August 2001 when it was acquired by Medtronic, Inc. Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of type 1 diabetes. Mr. Mann also founded and funded Medical Research Group (MRG) which was developing an artificial pancreas. MRG was also acquired by Medtronic in 2001. Mr. Mann's extensive experience with type 1 diabetes at MiniMed led him to explore therapies to improve outcomes for people with type 2 diabetes which is a pandemic challenging the entire world. Mannkind Corporation has developed an ultra-fast-acting insulin that mimics normal physiology. AFREZZA® will significantly improve care for early stage type 2 diabetics and along with the PerQFlo basal patch pump will more effectively treat type 1 and later type 2 diabetes.
Sorry, I can't provide a link because the link no longer works.
|
|
|
Post by babaoriley on Mar 23, 2014 22:53:48 GMT -5
"Thanks Brentie, it's tough being the most optimistic guy around."
You're right CapitalGrowth, er, I mean Spiro!
|
|